Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Influenza in Birds

• 2017 A/H7N9 IIV Revaccination
• Safety/Efficacy Study of Seqirus A/H7N9 IIV With or Without MF59(R) Adjuvant to Prevent Avian Influenza
• 2013/2017 H7N9 Prime-Boost Interval
• H5N1 With or Without Topical Aldara in Healthy Adults
• Co-Administration of AS03 Adjuvanted A/H7N9 IIV With IIV4
• Sanofi 2017 H7N9 With/Without AS03 in Adults/Elderly
• Two Doses of Multimeric-001 (M-001) Followed by Two Doses of an Influenza A/H7N9 Vaccine
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology
• H7N9 Vaccination With and Without AS03 and Unadjuvanted H3N2v Vaccination: Standard and Systems Biology Analyses
• H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults
• Safety and Pharmacokinetics Study of FBF001
• A Phase I Study Priming With an Inactivated A/H7N9 Influenza Virus Vaccine With or Without MF59 Adjuvant Followed by Live Attenuated A/H7N9 Influenza Virus Vaccine
• H7N9 Mix and Match With MF59 in Healthy Elderly Persons
• H7N9 Mix and Match With AS03 and MF59 in Healthy Adults
• H7N9 Mix and Match With MF59 in Healthy Adults
• H5N1 Vaccination With and Without AS03: Systems Biology Analysis
• Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine
• H5N1 Mix and Match With AS03
• H5N1 Mix and Match With MF59
• Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults
• Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally
• Pharmacologic Study of Oseltamivir in Healthy Volunteers
• Safety Study of Avian Flu Vaccine
• Dose-Escalating Trial Using Vero Cell-culture Derived H5N1 +/- Aluminum in Adults
• High-Dose Versus Standard-Dose Oseltamivir to Treat Severe Influenza and Avian Influenza
• Inactivated Influenza A/H5N1 Vaccine in the Elderly
• A/H5N1 Vaccine in Healthy Children Aged 2-9 Years